The rat prostate was used to investigate cell loss (numeric atrophy) and altered cell proliferation after castration. Cell loss was determined by the proportion of apoptotic bodies. The apoptotic index was considerable and reached a maximum in the coagulating gland on day 2 and in the other prostate lobes between days 4 and 8. Thereafter, cell loss was reduced and finally corresponded to that of control animals. Cell proliferation decreased and soon ceased at all. Androgen administration caused cell increase in all prostate lobes. Following a latent period of 35–40 h, the 3H-labeling index increased with a maximum on day 3. Values then fell and were minimal above control values. Rhythmically interrupted administration of testosterone resulted in a decreased ability to stimulate cell proliferation. This androgen-induced cell proliferation is a useful model for testing cell proliferation of the prostate. The combined determination of cell loss and the cell proliferation, therefore, may be important for the clinical examination of the hormonal responsiveness of prostatic carcinomas.

Keywords:
Cell proliferation, Autoradiography, Cell loss, Apoptotic bodies, Prostate, Castration, Testosterone
This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.